MiRNA-501-3p and MiRNA-502-3p: A promising biomarker panel for Alzheimer's disease

Abstract

Introduction: Alzheimer's disease (AD) lacks a less invasive and early detectable biomarker. Here, we investigated the biomarker potential of miR-501-3p and miR-502-3p using different AD sources.

Methods: MiR-501-3p and miR-502-3p expressions were evaluated in AD cerebrospinal fluid (CSF) exosomes, serum exosomes, familial and sporadic AD fibroblasts and B-lymphocytes by qRT-PCR analysis. Further, miR-501-3p and miR-502-3p expressions were analysed in APP, Tau plasmid transfected cells media exosomes and in different brain cell types.

Results: MiR-501-3p and miR-502-3p expressions were significantly up-regulated in AD CSF exosomes relative to controls. MiRNA levels were high in accordance with amyloid plaque and NFT density in multiple brain regions. Similarly, both miRNAs were elevated in AD and MCI serum exosomes compared with controls. MiR-502-3p expression was high in familial AD and sporadic AD B-lymphocytes. MiR-501-3p and miR-502-3p expression were elevated intracellularly and secreted extracellularly in response to APP and Tau pathology. Finally, neurons and astrocytes displayed high expression of these miRNAs.

Discussion: These results suggest that miR-501-3p and miR-502-3p could be promising biomarkers for AD.

Keywords

Alzheimer's disease / biomarker / CSF / MiR-501-3p / MiR-502-3p / serum

References

[1] 2023 Alzheimer's disease facts and figures. Alzheimers Dement. 2023; 19(4): 1598-1695.

[2] Khan S, Barve KH, Kumar MS. Recent advancements in pathogenesis, diagnostics and treatment of Alzheimer's disease. Curr Neuropharmacol. 2020; 18(11): 1106-1125.

[3] Devara D, Choudhary Y, Kumar S. Role of microRNA-502-3p in human diseases. Pharmaceuticals (Basel). 2023; 16(4): 532. Published 2023 Apr 2.

[4] Chen ZR, Huang JB, Yang SL, Hong FF. Role of cholinergic signaling in Alzheimer's disease. Molecules. 2022; 27(6): 1816. Published 2022 Mar 10.

[5] Comaposada-Baró R, Benito-Martínez A, Escribano-Saiz JJ, et al. Cholinergic neurodegeneration and cholesterol metabolism dysregulation by constitutive p75NTR signaling in the p75exonIII-KO mice. Front Mol Neurosci. 2023; 16: 1237458. Published 2023 Oct 13.

[6] Rabins PV, Rovner BW, Rummans T, Schneider LS, Tariot PN. Guideline watch (October 2014): practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Focus (Am Psychiatr Publ). 2017; 15(1): 110-128.

[7] Day GS, Scarmeas N, Dubinsky R, et al. Aducanumab use in symptomatic Alzheimer disease evidence in focus: a report of the AAN guidelines subcommittee. Neurology. 2022; 98(15): 619-631.

[8] Liu XY, Yang LP, Zhao L. Stem cell therapy for Alzheimer's disease. World J Stem Cells. 2020; 12(8): 787-802.

[9] Khan T, Waseem R, Shahid M, et al. Recent advancement in therapeutic strategies for Alzheimer's disease: insights from clinical trials [published online ahead of print, 2023 Oct 31]. Ageing Res Rev. 2023; 92: 102113.

[10] Gaetani L, Chiasserini D, Paolini Paoletti F, Bellomo G, Parnetti L. Required improvements for cerebrospinal fluid-based biomarker tests of Alzheimer's disease [published online ahead of print, 2023 Oct 30]. Expert Rev Mol Diagn. 2023; 23(12): 1195-1207.

[11] Rasmussen J, Langerman H. Alzheimer's disease—why we need early diagnosis. Degener Neurol Neuromuscul Dis. 2019; 9: 123-130. Published 2019 Dec 24.

[12] Vijayan M, Kumar S, Bhatti JS, Reddy PH. Molecular links and biomarkers of stroke, vascular dementia, and Alzheimer's disease. Prog Mol Biol Transl Sci. 2017; 146: 95-126.

[13] Owen M, Bose N, Nisenbaum L, Partrick KA, Fillit HM. The critical role of biomarkers for drug development targeting the biology of aging. J Prev Alzheimers Dis. 2023; 10(4): 729-742.

[14] Kanach C, Blusztajn JK, Fischer A, Delalle I. MicroRNAs as candidate biomarkers for Alzheimer's disease. Noncoding RNA. 2021; 7(1): 8. Published 2021 Feb 1.

[15] Zhao Y, Jaber V, Alexandrov PN, et al. microRNA-Based Biomarkers in Alzheimer's disease (AD). Front Neurosci. 2020; 14: 585432.

[16] Siedlecki-Wullich D, Miñano-Molina AJ, Rodríguez-Álvarez J. microRNAs as early biomarkers of Alzheimer's disease: a synaptic perspective. Cells. 2021; 10(1): 113. Published 2021 Jan 9.

[17] Kumar S, Reddy PH. Are circulating microRNAs peripheral biomarkers for Alzheimer's disease?. Biochim Biophys Acta. 2016; 1862(9): 1617-1627.

[18] Han YH, Xiang HY, Lee DH, et al. Identification and diagnostic potential of serum microRNAs as biomarkers for early detection of Alzheimer's disease [published online ahead of print, 2023 Nov 1]. Aging (Albany NY). 2023; 15: 12085-12103.

[19] O'Brien J, Hayder H, Zayed Y, Peng C. Overview of MicroRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol (Lausanne). 2018; 9: 402. Published 2018 Aug 3.

[20] Reddy PH, Williams J, Smith F, et al. MicroRNAs, aging, cellular senescence, and Alzheimer's disease. Prog Mol Biol Transl Sci. 2017; 146: 127-171.

[21] Kumar S, Chawla YK, Ghosh S, Chakraborti A. Severity of hepatitis C virus (genotype-3) infection positively correlates with circulating microRNA-122 in patients sera. Dis Markers. 2014: 435476.

[22] Kumar S, Vijayan M, Bhatti JS, Reddy PH. MicroRNAs as peripheral biomarkers in aging and age-related diseases. Prog Mol Biol Transl Sci. 2017; 146: 47-94.

[23] Samson JS, Parvathi VD. Prospects of microRNAs as therapeutic biomarkers in non-small cell lung cancer. Med Oncol. 2023; 40(12): 345. Published 2023 Nov 3.

[24] Naithani U, Jain P, Sachan A, Khare P, Gabrani R. MicroRNA as a potential biomarker for systemic lupus erythematosus: pathogenesis and targeted therapy [published online ahead of print, 2023 Nov 3]. Clin Exp Med. 2023; 23(8): 4065-4077.

[25] Rivera J, Gangwani L, Kumar S. Mitochondria localized microRNAs: an unexplored miRNA niche in Alzheimer's disease and aging. Cells. 2023; 12(5): 742. Published.

[26] Williams J, Smith F, Kumar S, Vijayan M, Reddy PH. Are microRNAs true sensors of ageing and cellular senescence?. Ageing Res Rev. 2017; 35: 350-363.

[27] Liu S, Fan M, Zheng Q, et al. MicroRNAs in Alzheimer's disease: potential diagnostic markers and therapeutic targets. Biomed Pharmacother. 2022; 148: 112681.

[28] Kumar S, Vijayan M, Reddy PH. MicroRNA-455-3p as a potential peripheral biomarker for Alzheimer's disease. Hum Mol Genet. 2017; 26(19): 3808-3822.

[29] Kumar S, Reddy PH. MicroRNA-455-3p as a potential biomarker for Alzheimer's disease: an update. Front Aging Neurosci. 2018; 10: 41. Published 2018 Feb 23.

[30] Kumar S, Reddy AP, Yin X, Reddy PH. Novel microRNA-455-3p and its protective effects against abnormal APP processing and amyloid beta toxicity in Alzheimer's disease. Biochim Biophys Acta Mol Basis Dis. 2019; 1865(9): 2428-2440.

[31] Kumar S, Morton H, Sawant N, et al. MicroRNA-455-3p improves synaptic, cognitive functions and extends lifespan: relevance to Alzheimer's disease. Redox Biol. Published online November 9, 2021.

[32] Kumar S, Reddy PH. Elevated levels of microRNA-455-3p in the cerebrospinal fluid of Alzheimer's patients: a potential biomarker for Alzheimer's disease. Biochim Biophys Acta Mol Basis Dis. 2021; 1867(4): 166052.

[33] Kumar S, Orlov E, Gowda P, et al. Synaptosome microRNAs regulate synapse functions in Alzheimer's disease. NPJ Genom Med. 2022; 7(1): 47. Published 2022 Aug 8.

[34] Kumar S. Synaptosome microRNAs: emerging synapse players in aging and Alzheimer's disease. Neural Regen Res. 2023; 18(6): 1275-1276.

[35] Sharma B, Torres MM, Rodriguez S, Gangwani L, Kumar S. MicroRNA-502-3p regulates GABAergic synapse function in hippocampal neurons. Neural Regen Res. 2024; 19(12): 2698-2707.

[36] Dalal S, Ramirez-Gomez J, Sharma B, Devara D, Kumar S. MicroRNAs and synapse turnover in Alzheimer's disease. Ageing Res Rev. 2024; 99: 102377.

[37] Risha Y, Minic Z, Ghobadloo SM, Berezovski MV. The proteomic analysis of breast cell line exosomes reveals disease patterns and potential biomarkers. Sci Rep. 2020; 10(1): 13572. Published 2020 Aug 11.

[38] Yang TT, Liu CG, Gao SC, Zhang Y, Wang PC. The serum exosome derived microRNA-135a, -193b, and -384 were potential Alzheimer's disease biomarkers. Biomed Environ Sci. 2018; 31(2): 87-96.

[39] Jack CR, MS Albert, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7(3): 257-262.

[40] Lee JC, Kim SJ, Hong S, Kim Y. Diagnosis of Alzheimer's disease utilizing amyloid and tau as fluid biomarkers. Exp Mol Med. 2019; 51(5): 1-10. Published 2019 May 9.

[41] Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008; 141(5): 672-675.

[42] Condrat CE, Thompson DC, Barbu MG, et al. miRNAs as Biomarkers in disease: latest findings regarding their role in diagnosis and prognosis. Cells; 9(2): 2020. Published 2020 Jan 23.

[43] Wang J, Chen J, Sen S. MicroRNA as biomarkers and diagnostics. J Cell Physiol. 2016; 231(1): 25-30.

[44] Tribolet L, Kerr E, Cowled C, et al. MicroRNA biomarkers for infectious diseases: from basic research to biosensing. Front Microbiol. 2020; 11: 1197. Published 2020 Jun 3.

[45] Galvão-Lima LJ, Morais AHF, Valentim RAM, Barreto EJSS. miRNAs as biomarkers for early cancer detection and their application in the development of new diagnostic tools. Biomed Eng Online. 2021; 20(1): 21. Published 2021 Feb 16.

[46] Rivera J, Sharma B, Torres MM, Kumar S. Factors affecting the GABAergic synapse function in Alzheimer's disease: focus on microRNAs. Ageing Res Rev. 2023; 92: 102123.

[47] Wichmann TO, Damkier HH, Pedersen M. A brief overview of the cerebrospinal fluid system and its implications for brain and spinal cord diseases. Front Hum Neurosci. 2022; 15: 737217. Published 2022 Jan 21.

[48] Pingle SC, Lin F, Anekoji MS, et al. Exploring the role of cerebrospinal fluid as analyte in neurologic disorders. Future Sci OA. 2023; 9(4): FSO851. Published 2023 Apr 4.

[49] Lehmann S, Schraen-Maschke S, Buée L, et al. Clarifying the association of CSF Aβ, tau, BACE1, and neurogranin with AT(N) stages in Alzheimer disease. Mol Neurodegener. 2024; 19(1): 66. Published 2024 Oct 8.

[50] Doyle LM, Wang MZ. Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis. Cells. 2019; 8(7): 727. Published 2019 Jul 15.

[51] Irala D, Wang S, Sakers K, et al. Astrocyte-secreted neurocan controls inhibitory synapse formation and function. Neuron. 2024; 112(10): 1657-1675.e10.

[52] Igarashi KM. Entorhinal cortex dysfunction in Alzheimer's disease. Trends Neurosci. 2023; 46(2): 124-136.

[53] Hara N, Kikuchi M, Miyashita A, et al. Serum microRNA miR-501-3p as a potential biomarker related to the progression of Alzheimer's disease. Acta Neuropathol Commun. 2017; 5(1): 10. Published 2017 Jan 31.

[54] Toyama K, Spin JM, Tsao PS, et al. Serum microRNA-501-3p is a potential diagnostic tool for detecting mild cognitive impairment: ehime genome study. J Neurochem. 2023; 166(6): 960-971.

[55] Krylova SV, Feng D. The machinery of exosomes: biogenesis, release, and uptake. Int J Mol Sci. 2023; 24(2): 1337. Published 2023 Jan 10.

[56] Hamdan Y, Mazini L, Malka G. Exosomes and micro-RNAs in aging process. Biomedicines. 2021; 9(8): 968. Published 2021 Aug 6.

[57] Yaniv Y, Juhaszova M, Sollott SJ. Age-related changes of myocardial ATP supply and demand mechanisms. Trends Endocrinol Metab. 2013; 24(10): 495-505.

[58] Zhang C, Rissman RA, Feng J. Characterization of ATP alternations in an Alzheimer's disease transgenic mouse model. J Alzheimers Dis. 2015; 44(2): 375-378.

[59] Wang MT, Wang YR, Zeng GH, et al. Phenotypic alterations in peripheral blood B lymphocytes of patients with Alzheimer's disease. J Prev Alzheimers Dis. 2025: 100135.

[60] Low YLC, Sun J, Huang X, et al. Profiling peripheral blood lymphocytes in Alzheimer's disease and mild cognitive impairment. Alzheimers Dement. 2025; 20(Suppl 2): e086090.

[61] Feng W, Zhang Y, Ding S, et al. B lymphocytes ameliorate Alzheimer's disease-like neuropathology via interleukin-35. Brain Behav Immun. 2023; 108: 16-31.

[62] Trushina E. Alzheimer's disease mechanisms in peripheral cells: promises and challenges. Alzheimers Dement (NY). 2019; 5: 652-660.

[63] Eysert F, Kinoshita PF, Lagarde J, et al. Mitochondrial alterations in fibroblasts from sporadic Alzheimer's disease (AD) patients correlate with AD-related clinical hallmarks. Acta Neuropathol Commun. 2024; 12(1): 90. Published 2024 Jun 8.

[64] Irala D, Wang S, Sakers K, et al. Astrocyte-secreted neurocan controls inhibitory synapse formation and function. Neuron. 2024; 112(10): 1657-1675. e10.

[65] Giacomucci G, Mazzeo S, Bagnoli S, et al. Plasma neurofilament light chain as a biomarker of Alzheimer's disease in subjective cognitive decline and mild cognitive impairment. J Neurol. 2022; 269(8): 4270-4280.

[66] Park SH, Lee EH, Kim HJ, et al. The relationship of soluble TREM2 to other biomarkers of sporadic Alzheimer's disease. Scientific reports. 2021; 11(1): 13050.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.